Growth arrest of immortalized human keratinocytes and suppression of telomerase activity by p21(WAF1) gene expression

Molecular Carcinogenesis

Volumn 21, Issue 1, 1998, Pages 26-36

  Kallassy, Mireille ^a   Martel, Nicole ^a   Damour, Odile ^b   Yamasaki, Hiroshi ^a   Nakazawa, Hisayoshi ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

HaCaT; Human keratinocytes; p21(WAF1); p53; telomerase

Indexed keywords

PROTEIN P21; PROTEIN P53; TELOMERASE;

ARTICLE; CELL IMMORTALIZATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; KERATINOCYTE; PRIORITY JOURNAL; SKIN CARCINOGENESIS; TUMOR SUPPRESSOR GENE; ULTRAVIOLET B RADIATION;

CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; KERATINOCYTES; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TELOMERASE; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEIN P53;

UNIDENTIFIED RETROVIRUS;

EID: 0031933319     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199801)21:1<26::AID-MC5>3.0.CO;2-N     Document Type: Article

References (86)

1. Ziegler A, Jonason AS, Leffell DJ, et al. Sunburn and p53 in the onset of skin cancer. Nature 372:773-776, 1994.
2. Ziegler A, Leffell DJ, Kunala S, et al. Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci USA 90:4216-4220, 1993.
3. IARC. Solar and ultraviolet radiation. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol 55. International Agency for Research on Cancer, Lyon, 1992.
4. Nakazawa H, English D, Randell PL, et al. UV and skin cancer: Specific p53 gene mutation in normal skin as a biologically relevant exposure measurement. Proc Natl Acad Sci USA 91:360-364, 1994.
5. Jonason AS, Kunala S, Price GJ, et al. Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci USA 93:14025-14029, 1996.
6. Arrowsmith CH, Morin P. New insights into p53 function from structural studies. Oncogene 12:1379-1385, 1996.
7. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825, 1993.
8. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311, 1991.
9. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245, 1992.
10. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299, 1995.
11. Okamoto K, Beach D. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J 13:4816-4822, 1994.
12. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362:857-860, 1993.
13. Hoppe-Seyler F, Butz K. Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53. J Virol 67:3111-3117, 1993.
14. Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 10:1565-1569, 1991.
15. Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J 12:461-468, 1993.
16. Olson DC, Marechal V, Momand J, Chen J, Romocki C, Levine AJ. Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene 8:2353-2360, 1993.
17. Martin K, Trouche D, Hagemeier C, Sorensen T, La Thangue N, Kouzarides T, Stimulation of E2F1/DP1, transcriptional activity by MDM2 oncoprotein. Nature 375:691-694, 1995.
18. Xiao ZX, Chen J, Levine AJ, etal. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375:694-698, 1995.
19. Ueda M, Ahmed NU, Bito T, Nagano T, Ichihashy M. Expression of retinobtastoma protein in epidermis is induced by UVB exposure. Br J Dermatol 135:406-411, 1996.
20. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 81323-330, 1995.
21. 1 cyclin-dependent kinases. Genes Dev 9:1149-1163, 1995.
22. INK4. Science 267:249-252, 1995.
23. Demetrick DJ, Matsumoto S, Hannon GJ, et al. Chromosomal mapping of the genes for the human cell cycle proteins cyclin C (CCNC), cyclin E (CCNE), p21 (CDKN1)and KAP (CDKN3). Cytogenet Cell Genet 69:190-192, 1995.
24. 1 cyclin-dependent kinases. Cell 75:805-816, 1993.
25. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 211:90-98, 1994.
26. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369:574-578, 1994.
27. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 366.701-704, 1993.
28. Smith JR. Inhibitors of DMA synthesis derived from senescent human diploid fibroblasts. Exp Gerontol 27:409-412, 1992.
29. 0 and entry into the cell cycle of cells expressing p21Sdi1 antisense RNA. Proc Natl Acad Sci USA 92:4352-4356, 1995.
30. Halevy O, Novitch BG, Spicer DB, et al. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 267:1018-1021, 1995.
31. Parker SB, Eichele G, Zhang P, et al. p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science 267:1024-1027, 1995.
32. Healy E, Reynolds NJ, Smith MD, et al. Upregulation of p21WAF1/ CIP1 in psoriasis and after the application of irritants and tape stripping. J Invest Dermatol 105:274-279, 1995.
33. Steinman RA, Huffman B, Iro A, Guillouf C, Liebermann DA, El-Houseini ME. Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene 9:3389-3396, 1994.
34. Jiang H, Lin J, Su ZZ, Collart FR, Huberman E, Fisher PB. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene 9:3397-3406, 1994.
35. 1 arrest. Cell 76:1013-1023, 1994.
36. 1 arrest and apoptosis. Cancer Res 54:1169-1174, 1994.
37. Johnson M, Dimitrov D, Vojta PJ, et al. Evidence for a p53-independent pathway for upregulation of SDI1/CIP1/WAF1/p21 RNA in human cells. Mol Carcinog 11:59-64, 1994.
38. Shiohara M, el-Deiry WS, Wada M. Absence of WAF1 mutations in a variety of human malignancies. Blood 84:3781-3784, 1994.
39. Chen Y, Cipriano S, Arenkiel J, Miller F. Tumor suppression by P21WAF1. Cancer Res 55:4536-4539, 1995.
40. Eastham J, Hall S, Sehgal I, et al. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 55:5151-5155, 1995.
41. Chen J, Willingham T, Shuford M, et al. Effects of ectopic overexpression of p21WAF1/CIP1 on aneuoploidy and the malignant phenotype of human brain tumor cells. Oncogene 13:1395-1403, 1996.
42. Yang Z, Perkins N, Ohno T, Nabel E, Nabel G. The p21 cyclin- dependent kinase inhibitor suppresses tumorigenicity in vivo. Nat Med 1:1052-1056, 1995.
43. Missero C, Di Cunto F, Kiyokawa H, Koff A, Dotto P, The absence of p21Cip1/WAF1 alters keratinocyte growth and differentiation and promotes ras-tumors progression. Genes Dev 10:3065-3075, 1996.
44. Feng J, Funk WD, Wang SS, et al. The RNA component of human telomerase. Science 269:1236-1241, 1995.
45. Greider CW, Blackburn EH. Tetomeres, telomerase and cancer. Sci Am 274:92-97, 1996.
46. Kim NW, Piatyszek,MA, Prowse KR, etal. Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011-2015, 1994.
47. Holt SE, Wright WE, Shay JW. Regulation of telomerase activity in immortal cell lines. Mol Cell Biol 16:2932-2939, 1996.
48. Soder A, Hoare S, Muir S, Going J, Parkinson EK, Keith WN. Amplification, increased dosage and in situ expression of the telomerase RNA gene in human cancer. Oncogene 14:1013-1021, 1997.
49. Ueda M, Ouhtit A, Bito T, et al. Evidence for UV-associated activation of telomerase in human skin. Cancer Res 57:370-374, 1997.
50. Nakazawa K, Darnour O, Collombel C. Modulation of normal human melanocyte dendricity by growth-promoting agents. Pigment Cell Res 6:406-416, 1993.
51. Hawley-Nelson P, Sullivan JE, Kung M, Hennings H, Yuspa SH. Optimized conditions for the growth of human epidermal cells in culture. J Invest Dermatol 75:176-182, 1980.
52. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 106:761-771, 1988.
53. Boukamp P, Stanbridge EJ, Foo DY, Cerutti PA, Fusenig NE. c-Ha-ras oncogene expression in immortalized human keratinocytes (HaCaT) alters growth potential in vivo but tacks correlation with malignancy. Cancer Res 50:2840-2847, 1990.
54. Miller D, Miller D, Garcia V, Lynch C. Use of retroviral vectors for gene transfer and expression. Methods Enzymol 271:581-599, 1990.
55. Lane DP, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. Nature 278:261-263, 1979.
56. Spandau DF. Distinct conformations of p53 are observed at different stages of keratinocyte differentiation. Oncogene 9:1861-1868, 1994.
57. Wright WE, Shay JW, Piatyszek MA. Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity. Nucleic Acids Res 23:3794-3795, 1995.
58. Tachibana O, Nakazawa H, Lampe J, Watanabe K, Kleihues P, Ohgaki H. Expression of Fas/APO-1 during the progression of astrocytomas. Cancer Res 55:5528-5530, 1995.
59. Hawley-Nelson P, Stanley JR, Schmidt J, Gullino M, Yuspa SH. The tumor promoter, 12-O-tetradecanoylphorbol-13-acetate accelerates keratinocyte differentiation and stimulates growth of an unidentified cell type in cultured human epidermis. Exp Cell Res 137:155-167, 1982.
60. Lichti U, Patterson E, Hennings H, Yuspa SH. The tumor promoter 12-O-tetradecanoylphorbol-13-acetate induces ornithine decarboxylase in proliferating basal cells but not in differentiating cells from mouse epidermis. J Cell Physiol 107:261-267, 1981.
61. 1 independent of effects on gene transcription. Cancer Res 55:3928-3932, 1995.
62. Masui T, Wakefield LM, Lechner JF, LaVeck MA, Sporn MB, Harris CC. Type β transforming growth factor is the primary differentiation-inducing serum factor for normal bronchial epithelial cells. Proc Natl Acad Sci USA 83:2438-2442, 1986.
63. Hawley-Nelson P, Roop DR, Cheng CK, Yuspa SH. Regulated synthesis of low-molecular-weight antigens in keratinocyte cell cultures. J Invest Dermatol 87:454-459, 1986.
64. Coffey R, Jr., Sipes NJ, Bascom CC, et al. Growth modulation of mouse keratinocytes by transforming growth factors. Cancer Res 48:1596-1602, 1988.
65. Lehman TA, Modali R, Boukamp P, et al. p53 mutations in human immortalized epithelial cell lines. Carcinogenesis 14:833-839, 1993.
66. Dumaz N, Drougard C, Sarasin A, Daya-Grosjean L. Specific UV- induced mutation spectrum in thep53 gene of skin tumors from DNA-repair-deficientxerodermaipigmentosum patients: Proc Natl Acad Sci USA 90:10529-10533, 1993.
67. Enders GH, Koh J, Missero C, Rustgi A, Harlow E. p16 inhibition of transformed and primary squamous epithelial cells. Oncogene 12:1239-1245, 1996.
68. Guan KL, Jenkins CW, Li Y, et al, Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 8:2939-2952, 1994.
69. Zhang W, Grasso L, McClain CD, et al. p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res 55:668-674, 1995.
70. Zeng YX, el-Deiry WS. Regulation of p21WAF1/CIP1 expres sion by p53-independent pathways. Oncogene 12:1557-1564, 1996.
71. Xu D, Gruber A, Peterson C, Pisa P. Suppression of telomerase activity in HL60 cells after treatment with differentiating agents. Leukemia 10:1354-1357, 1996.
72. Savoysky E, Yoshida K, Ohtomo T, et al. Down-regulation of telomerase activity is an early event in the differentiation of HL60 cells. Biochem Biophys Res Commun 226:329-334, 1996.
73. Lane DP. p53, guardian of the genome. Nature 358:15-16, 1992.
74. Weinberg WC, Azzoli CG, Chapman K, Levine AJ, Yuspa SH. p53-mediated transcriptional activity increases in differentiating epidermal keratinocytes in association with decreased p53 protein. Oncogene 10:2271-2279, 1995.
75. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378:203-206, 1995.
76. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378:206-208, 1995.
77. Chen J, Lin J, Levine AJ. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol Med 1:142-152, 1995.
78. Haines DS, Landers JE, Engle U, George DL. Physical and functional interaction between wild-type p53 and mdm2 proteins. Mol Cell Biol 14:1171-1178, 1994.
79. Chen J, Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 13:4107-4114, 1993.
80. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregu- latory feedback loop. Genes Dev 7:1126-1132, 1993.
81. Pan H, Griep AE. Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice: Implications for tumor suppressor gene function. Genes Dev 8:1285-1299, 1994.
82. Morgenbesser SD, Williams BO, Jacks T, DePinho RA. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature 371:72-74, 1994.
83. White E. p53, guardian of Rb. Nature 371:21-22, 1994.
84. Chen J, Willingham T, Shuford M, et al. Effects of ectopic overexpression of p21WAF1/CIP1 on aneuploidy and the malignant phenotype of human brain tumor cells. Oncogene 13:1395-1403, 1996.
85. Greider CW. Telomerase and telomere-length regulation: Lessons from small eukaryotes to mammals. Cold Spring Harb Symp Quant Biol 58:719-723, 1993.
86. Luo Y, Hurwitz J, Massague J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature 375:159-161, 1995.